150 S Saunder Road
About Horizon Therapeutics
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter or like us on Facebook.
Stock symbol: HZNP
At Horizon, we work to define ourselves by a different set of numbers - the number of patients helped, lives changed, lives saved. In this video, hear from our employees on why working at Horizon Pharma is personal.
370 articles with Horizon Therapeutics
Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September:
Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results;Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million
Dr. Mahony brings more than three decades of broad cross-functional and global experience to the board.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the availability of an expanded access program for its investigational medicine teprotumumab.
Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
Since 2016, Horizon’s partnership with MSA has focused on three areas of giving: infrastructure, programming and employee engagement.
Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
The FDA is expected to make a decision on the approval of the proposed new dosage form of granules in packets in 2020.
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027.
Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational medicine teprotumumab for the treatment of active thyroid eye disease.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019
Horizon Therapeutics plc (Nasdaq: HZNP) is elevating the dialogue on gout within the medical and scientific community during the Annual European Congress of Rheumatology (EULAR 2019) with a series of data presentations on gout and its systemic implications
Horizon Therapeutics plc, announced that the company will participate in the following conference in June
New program improves access and speed to receiving a diagnosis for people and extended family members who may be living with Urea Cycle Disorders
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “Best Workplaces in Chicago” list
Research that has redefined the trajectory and true impact of the disease underscores the campaign
Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Horizon Therapeutics plc announced its first-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.
The restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date.